Is FOCL or BWAY more profitable?

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% Brainsway 15.65% 12.74% 8.17%

Does the media prefer FOCL or BWAY?

In the previous week, FocalTherics had 20 more articles in the media than Brainsway. MarketBeat recorded 22 mentions for FocalTherics and 2 mentions for Brainsway. FocalTherics' average media sentiment score of 1.25 beat Brainsway's score of 0.56 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TCMD or FOCL?

In the previous week, FocalTherics had 21 more articles in the media than Tactile Systems Technology. MarketBeat recorded 22 mentions for FocalTherics and 1 mentions for Tactile Systems Technology. FocalTherics' average media sentiment score of 1.25 beat Tactile Systems Technology's score of 0.92 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tactile Systems Technology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, FOCL or NPCE?

NeuroPace has higher revenue and earnings than FocalTherics. NeuroPace is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.19 -$29.25M -$1.03 N/A NeuroPace $99.99M 4.82 -$21.47M -$0.57 N/A

Is FOCL or NPCE more profitable?

NeuroPace has a net margin of -19.34% compared to FocalTherics' net margin of -56.26%. NeuroPace's return on equity of -105.64% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% NeuroPace -19.34% -105.64% -16.51%

Does the media favor FOCL or NPCE?

In the previous week, FocalTherics had 10 more articles in the media than NeuroPace. MarketBeat recorded 22 mentions for FocalTherics and 12 mentions for NeuroPace. FocalTherics' average media sentiment score of 1.25 beat NeuroPace's score of 0.39 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLPT or FOCL?

In the previous week, FocalTherics had 20 more articles in the media than ClearPoint Neuro. MarketBeat recorded 22 mentions for FocalTherics and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.70 beat FocalTherics' score of 1.25 indicating that ClearPoint Neuro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive FocalTherics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

FocalTherics (FOCL) Competitors

$4.13 -0.11 (-2.59%)

As of 08/21/2026 04:00 PM Eastern

Compare

FOCL vs. BWAY, DCTH, TCMD, NPCE, and CLPT

Should you buy FocalTherics stock or one of its competitors? FocalTherics's main competitors and comparable companies include Brainsway (BWAY), Delcath Systems (DCTH), Tactile Systems Technology (TCMD), NeuroPace (NPCE), and ClearPoint Neuro (CLPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does FocalTherics compare to Brainsway?

FocalTherics (NASDAQ:FOCL) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

FocalTherics currently has a consensus price target of $7.75, suggesting a potential upside of 87.65%. Brainsway has a consensus price target of $16.95, suggesting a potential upside of 14.99%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Brainsway	15.65%	12.74%	8.17%

Brainsway has lower revenue, but higher earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50

In the previous week, FocalTherics had 20 more articles in the media than Brainsway. MarketBeat recorded 22 mentions for FocalTherics and 2 mentions for Brainsway. FocalTherics' average media sentiment score of 1.25 beat Brainsway's score of 0.56 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats FocalTherics on 11 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Delcath Systems?

FocalTherics (NASDAQ:FOCL) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

FocalTherics presently has a consensus price target of $7.75, indicating a potential upside of 87.65%. Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 35.16%. Given FocalTherics' higher possible upside, equities analysts plainly believe FocalTherics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Delcath Systems has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A
Delcath Systems	$85.23M	6.98	$2.70M	$0.01	1,714.00

Delcath Systems has a net margin of 0.56% compared to FocalTherics' net margin of -56.26%. Delcath Systems' return on equity of 0.46% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Delcath Systems	0.56%	0.46%	0.42%

In the previous week, FocalTherics had 22 more articles in the media than Delcath Systems. MarketBeat recorded 22 mentions for FocalTherics and 0 mentions for Delcath Systems. FocalTherics' average media sentiment score of 1.25 beat Delcath Systems' score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Positive
Delcath Systems	Neutral

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Delcath Systems beats FocalTherics on 12 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tactile Systems Technology currently has a consensus price target of $38.40, indicating a potential upside of 61.21%. FocalTherics has a consensus price target of $7.75, indicating a potential upside of 87.65%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Tactile Systems Technology has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.64	$19.09M	$1.08	22.06
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A

Tactile Systems Technology has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, FocalTherics had 21 more articles in the media than Tactile Systems Technology. MarketBeat recorded 22 mentions for FocalTherics and 1 mentions for Tactile Systems Technology. FocalTherics' average media sentiment score of 1.25 beat Tactile Systems Technology's score of 0.92 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tactile Systems Technology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tactile Systems Technology has a net margin of 7.10% compared to FocalTherics' net margin of -56.26%. Tactile Systems Technology's return on equity of 11.49% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	7.10%	11.49%	9.17%
FocalTherics	-56.26%	-248.00%	-44.69%

Summary

Tactile Systems Technology beats FocalTherics on 11 of the 17 factors compared between the two stocks.

How does FocalTherics compare to NeuroPace?

FocalTherics (NASDAQ:FOCL) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

FocalTherics has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

NeuroPace has higher revenue and earnings than FocalTherics. NeuroPace is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A
NeuroPace	$99.99M	4.82	-$21.47M	-$0.57	N/A

FocalTherics presently has a consensus price target of $7.75, suggesting a potential upside of 87.65%. NeuroPace has a consensus price target of $19.29, suggesting a potential upside of 37.46%. Given FocalTherics' higher probable upside, equities analysts plainly believe FocalTherics is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, FocalTherics had 10 more articles in the media than NeuroPace. MarketBeat recorded 22 mentions for FocalTherics and 12 mentions for NeuroPace. FocalTherics' average media sentiment score of 1.25 beat NeuroPace's score of 0.39 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeuroPace has a net margin of -19.34% compared to FocalTherics' net margin of -56.26%. NeuroPace's return on equity of -105.64% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
NeuroPace	-19.34%	-105.64%	-16.51%

Summary

NeuroPace beats FocalTherics on 12 of the 16 factors compared between the two stocks.

How does FocalTherics compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

ClearPoint Neuro has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, FocalTherics had 20 more articles in the media than ClearPoint Neuro. MarketBeat recorded 22 mentions for FocalTherics and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.70 beat FocalTherics' score of 1.25 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
FocalTherics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ClearPoint Neuro currently has a consensus target price of $25.67, indicating a potential upside of 66.77%. FocalTherics has a consensus target price of $7.75, indicating a potential upside of 87.65%. Given FocalTherics' stronger consensus rating and higher probable upside, analysts plainly believe FocalTherics is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

ClearPoint Neuro has higher earnings, but lower revenue than FocalTherics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.70	-$25.54M	-$1.18	N/A
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A

FocalTherics has a net margin of -56.26% compared to ClearPoint Neuro's net margin of -81.76%. ClearPoint Neuro's return on equity of -188.09% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
FocalTherics	-56.26%	-248.00%	-44.69%

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

FocalTherics beats ClearPoint Neuro on 10 of the 17 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$154.80M	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.53%	11.08%
P/E Ratio	-4.01	26.67	272.60	24.24
Price / Sales	2.19	45.38	618.96	99.81
Price / Cash	N/A	33.24	78.62	53.99
Price / Book	-45.89	6.23	13.05	6.20
Net Income	-$29.25M	$150.07M	$3.47B	$348.59M
7 Day Performance	-13.24%	0.69%	2.09%	0.08%
1 Month Performance	-32.18%	8.91%	6.64%	3.88%
1 Year Performance	N/A	8.07%	25.02%	16.98%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	4.1115 of 5 stars	$4.13 -2.6%	$7.75 +87.7%	N/A	$154.80M	$70.53M	N/A	230	Earnings Report Upcoming Earnings
BWAY Brainsway	4.3825 of 5 stars	$14.66 -5.4%	$16.95 +15.6%	+93.9%	$588.32M	$60.70M	33.32	120	Analyst Downgrade
DCTH Delcath Systems	2.8688 of 5 stars	$16.86 -1.1%	$23.17 +37.4%	+54.1%	$585.03M	$95.42M	1,687.69	60	Analyst Downgrade
TCMD Tactile Systems Technology	3.9787 of 5 stars	$23.85 -3.0%	$38.40 +61.0%	+80.0%	$540.20M	$329.52M	22.08	1,086
NPCE NeuroPace	3.9592 of 5 stars	$14.47 +1.3%	$19.29 +33.3%	+56.1%	$496.67M	$106.99M	N/A	170	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. BWAY, DCTH, TCMD, NPCE, and CLPT

How does FocalTherics compare to Brainsway?

Summary

How does FocalTherics compare to Delcath Systems?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Summary

How does FocalTherics compare to NeuroPace?

Summary

How does FocalTherics compare to ClearPoint Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. BWAY, DCTH, TCMD, NPCE, and CLPT

How does FocalTherics compare to Brainsway?

Which has more risk & volatility, FOCL or BWAY?

Do insiders & institutionals hold more shares of FOCL or BWAY?

Do analysts recommend FOCL or BWAY?

Is FOCL or BWAY more profitable?

Which has preferable earnings and valuation, FOCL or BWAY?

Does the media prefer FOCL or BWAY?

Summary

How does FocalTherics compare to Delcath Systems?

Which has more risk & volatility, FOCL or DCTH?

Do analysts recommend FOCL or DCTH?

Which has preferable earnings & valuation, FOCL or DCTH?

Is FOCL or DCTH more profitable?

Does the media prefer FOCL or DCTH?

Do insiders & institutionals believe in FOCL or DCTH?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Do institutionals and insiders hold more shares of TCMD or FOCL?

Do analysts prefer TCMD or FOCL?

Which has better earnings & valuation, TCMD or FOCL?

Which has more volatility and risk, TCMD or FOCL?

Does the media favor TCMD or FOCL?

Is TCMD or FOCL more profitable?

Summary

How does FocalTherics compare to NeuroPace?

Which has more risk and volatility, FOCL or NPCE?

Which has stronger valuation & earnings, FOCL or NPCE?

Do analysts recommend FOCL or NPCE?

Does the media favor FOCL or NPCE?

Do insiders and institutionals hold more shares of FOCL or NPCE?

Is FOCL or NPCE more profitable?

Summary

How does FocalTherics compare to ClearPoint Neuro?

Which has more volatility and risk, CLPT or FOCL?

Does the media favor CLPT or FOCL?

Do analysts rate CLPT or FOCL?

Which has higher valuation and earnings, CLPT or FOCL?

Is CLPT or FOCL more profitable?

Do insiders and institutionals believe in CLPT or FOCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools